Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

146.43 +4.02 (+2.82%)

Delayed Quote Updated: 1:02 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

59 60 Next >

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Potentially Undervalued Stock With Strong Fundamentals ↗

July 19, 2025

NOVARTIS AG (NYSE:NVS) presents a value opportunity with strong profitability, financial health, and reasonable growth, trading below industry and market valuations.

Via Chartmill

Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses ↗

July 17, 2025

The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone.

Via Investor's Business Daily

Topics Government Stocks

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback ↗

July 17, 2025

Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales.

Via Benzinga

Earnings Scheduled For July 17, 2025 ↗

July 17, 2025

Via Benzinga

Earnings Outlook For Novartis ↗

July 16, 2025

Via Benzinga

Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report ↗

July 11, 2025

Via Stocktwits

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

Divi’s Labs Shares Dip After Patent Loss: SEBI RA Recommends Buy On Dips ↗

July 14, 2025

The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto.

Via Stocktwits

Topics Intellectual Property

This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It? ↗

July 12, 2025

Via The Motley Fool

Topics ETFs

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Via Benzinga

How Do Investors Really Feel About Novartis? ↗

July 10, 2025

Via Benzinga

Novartis Gets Swiss Approval For First Malaria Drug For Babies ↗

July 08, 2025

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.

Via Benzinga

Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants ↗

July 08, 2025

The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania.

Via Stocktwits

Topics Death Government

$1,000 in VEA Could Turn Into $57,000 ↗

July 08, 2025

Via The Motley Fool

Topics ETFs Economy

Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...' ↗

July 07, 2025

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Via Benzinga

Topics Artificial Intelligence

Better Dividend ETF to Buy for Passive Income: SCHD or GCOW ↗

July 03, 2025

Via The Motley Fool

Topics ETFs Stocks

Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish ↗

July 03, 2025

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.

Via Stocktwits

Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial ↗

July 03, 2025

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

Via Benzinga

Is Pfizer Stock a Yield Trap? ↗

July 03, 2025

Via The Motley Fool

Topics Intellectual Property

FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning ↗

June 30, 2025

The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.

Via Stocktwits

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

Could This Be the Best High-Dividend ETF to Buy Right Now? ↗

June 30, 2025

Via The Motley Fool

Topics ETFs Economy

Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗

June 27, 2025

Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.

Via Stocktwits

Topics Intellectual Property

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗

June 25, 2025

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Via Benzinga

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations ↗

June 23, 2025

Via Stocktwits

Topics Cannabis

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗

June 23, 2025

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Via Benzinga

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals ↗

June 23, 2025

NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector.

Via Chartmill

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at /week.